Protagonist Therapeutics Secures $14,000,000 Series B Round

  • Feed Type
  • Date
    6/5/2013
  • Company Name
    Protagonist Therapeutics
  • Mailing Address
    1455 Adams Drive Menlo Park, CA 94025
  • Company Description
    Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable.
  • Website
    http://www.protagonist-inc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $14,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The new funding will support the discovery and development of Protagonist’s pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.
  • M&A Terms
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Starfish Ventures